Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Doxorubicin and ifosfamide were the two key drugs that had been widely used for unresectable advanced recurrent soft tissue sarcoma until the recent approval of pazopanib, a molecular targeted drug,for public insurance coverage. The use of pazopanib is increasing worldwide. Pazopanib is a selective oral tyrosine kinase inhibitor that acts on vascular endothelial growth factor receptors (VEGF-R) and inhibits angiogenesis. Recently, it has been shown to exhibit inhibitory effects on platelet-derived growth factor receptors (PDGF-R) and a stem cell factor receptor (c-Kit). Moreover, pazopanib was shown to inhibit directly the proliferation of synovial sarcoma cells and block the PI3K-AKT pathway.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi